| Drug General Information |
| Drug ID |
D0R0TE
|
| Former ID |
DNC005718
|
| Drug Name |
3-(6-Ethoxy-naphthalen-2-yl)-pyridine
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C17H15NO
|
| Canonical SMILES |
CCOC1=CC2=C(C=C1)C=C(C=C2)C3=CN=CC=C3
|
| InChI |
1S/C17H15NO/c1-2-19-17-8-7-13-10-14(5-6-15(13)11-17)16-4-3-9-18-12-16/h3-12H,2H2,1H3
|
| InChIKey |
CQLHDOYGDGBDQA-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Cytochrome P450 19 |
Target Info |
Inhibitor |
[1]
|
|---|
| Cytochrome P450 11B1, mitochondrial |
Target Info |
Inhibitor |
[1]
|
| 17 alpha-hydroxylase-C17, 20-lyase |
Target Info |
Inhibitor |
[1]
|
|
BioCyc Pathway
|
Superpathway of steroid hormone biosynthesis
|
|
Estradiol biosynthesis II
|
|
Estradiol biosynthesis IPWY-7305:Superpathway of steroid hormone biosynthesis
|
|
Glucocorticoid biosynthesis
|
|
Mineralocorticoid biosynthesisPWY-7305:Superpathway of steroid hormone biosynthesis
|
|
Androgen biosynthesis
|
|
KEGG Pathway
|
Steroid hormone biosynthesis
|
|
Metabolic pathways
|
|
Ovarian steroidogenesishsa00140:Steroid hormone biosynthesis
|
|
Metabolic pathwayshsa00140:Steroid hormone biosynthesis
|
|
Ovarian steroidogenesis
|
|
Prolactin signaling pathway
|
|
NetPath Pathway
|
FSH Signaling Pathway
|
|
PANTHER Pathway
|
Androgen/estrogene/progesterone biosynthesis
|
|
PathWhiz Pathway
|
Androgen and Estrogen MetabolismPW000141:SteroidogenesisPW000045:Androgen and Estrogen Metabolism
|
|
Steroidogenesis
|
|
Reactome
|
Endogenous sterolsR-HSA-194002:Glucocorticoid biosynthesis
|
|
Endogenous sterolsR-HSA-193048:Androgen biosynthesis
|
|
Glucocorticoid biosynthesis
|
|
Endogenous sterols
|
|
WikiPathways
|
Metapathway biotransformation
|
|
Tryptophan metabolism
|
|
Oxidation by Cytochrome P450
|
|
Ovarian Infertility Genes
|
|
Metabolism of steroid hormones and vitamin D
|
|
FSH signaling pathway
|
|
Integrated Breast Cancer Pathway
|
|
Phase 1 - Functionalization of compoundsWP702:Metapathway biotransformation
|
|
Corticotropin-releasing hormoneWP702:Metapathway biotransformation
|
|
Steroid Biosynthesis
|
|
Glucocorticoid & Mineralcorticoid Metabolism
|
|
Prostate Cancer
|
|
Phase 1 - Functionalization of compounds
|
| References |
| REF 1 | J Med Chem. 2005 Oct 20;48(21):6632-42.Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis. |
|---|
